Ortanol (Omeprazole)

Omeprazole, the active ingredient in Ortanol, is a proton pump inhibitor presented as an oral dosage form for systemic use. It reduces gastric acid production and is employed to manage acid‑related conditions such as reflux disease and ulcers in adult patients.

GNH USA supplies Ortanol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable logistics across multiple regions. The product meets European Union manufacturing standards and is exported under strict quality controls.

Ortanol (omeprazole) is indicated for several acid‑related disorders where suppression of gastric acid provides therapeutic benefit.

Gastroesophageal reflux disease (GERD): alleviates heartburn and regurgitation, promotes healing of erosive esophagitis, and reduces acid exposure. Peptic ulcer disease: facilitates ulcer healing in the stomach and duodenum by maintaining a higher gastric pH. Helicobacter pylori eradication (in combination therapy): enhances the efficacy of antibiotics by creating a less acidic environment for bacterial clearance. Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors, reducing ulcer risk.

Omeprazole is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate pain often transient. - Diarrhea: loose stools that may resolve with continued therapy. - Nausea: feeling of queasiness, especially after first doses. - Abdominal pain: discomfort or cramping in the stomach area.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Low magnesium (hypomagnesemia): muscle cramps, irregular heartbeat, seizures in prolonged use.

When prescribing or dispensing Ortanol, several precautionary measures should be observed to ensure safe use. - Assess renal function: adjust therapy in patients with severe renal impairment. - Monitor magnesium levels: prolonged treatment may cause hypomagnesemia. - Evaluate for hypersensitivity: discontinue immediately if allergic signs appear. - Use caution in elderly: increased risk of bone fractures with long‑term use. - Store at room temperature: keep in the original container, protect from moisture.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines; awareness of key interactions helps avoid therapeutic failures or toxicity.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet activation leading to decreased efficacy. - Atorvastatin and other CYP2C19 substrates: increased plasma concentrations and risk of adverse effects. - High‑dose methotrexate: impaired renal clearance may raise toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR and bleeding risk. - Digoxin: elevated serum levels may cause toxicity. - Diazepam: enhanced sedation due to higher drug exposure.